A report by Kristina Lybecker of the Fraser Institute, a Canadian public think tank, states that the country's weak protection of intellectual property in the pharmaceutical sector could hamper Canada's ability to negotiate global trade agreements and boost economic growth. Stronger intellectual property laws would reduce litigation, lower trade barriers, strengthen research and development, create jobs in the pharmaceutical sector and encourage medical innovation, Lybecker said, adding that these benefits would compensate for the estimated increase in drug expenditures of about $352 million to $866 million a year.

Full Story:
PharmaTimes (U.K.)

Related Summaries